Nanoparticles Loaded with Docetaxel and Resveratrol as an Advanced Tool for Cancer Therapy

Abstract

A growing interest in the use of a combination of chemosensitizers and cytostatics for overcoming cancer resistance to treatment and the development of their delivery systems has been observed. Resveratrol (Res) presents antioxidant, anti-inflammatory and chemopreventive properties but also limits multidrug resistance against docetaxel (Dtx), which is one of the main causes of failure in cancer therapy with this drug. However, the use of both drugs presents challenges, including poor bioavailability, the unfavourable pharmacokinetics and chemical instability of Res and the poor water solubility and dose-limiting toxicity of Dtx. In order to overcome these difficulties, attempts have been made to create different forms of delivery for both agents. This review is focused on the latest developments in nanoparticles for the delivery of Dtx, Res and for the combined delivery of those two drugs. The aim of this review was also to summarize the synergistic mechanism of action of Dtx and Res on cancer cells. According to recent reports, Dtx and Res loaded in a nano-delivery system exhibit better efficiency in cancer treatment compared to free drugs. Also, the co-delivery of Dtx and Res in one actively targeted delivery system providing the simultaneous release of both drugs in cancer cells has a chance to fulfil the requirements of effective anticancer therapy and reduce limitations in therapy caused by multidrug resistance (MDR).

The use of integrated text mining and protein-protein interaction approach to evaluate the effects of combined chemotherapeutic and chemopreventive agents in cancer therapy

“…Thus, it is suggested that new methods of intelligent drug delivery should be used in addition to targeting the hub genes obtained in this study to achieve the effective performance of combination therapy with these two types of agents. For example, a study illustrated that nanoparticles loaded with docetaxel and resveratrol made HER-2-positive breast cancer cells sensitive to docetaxel [ 51 ].…”

Plants as a Source of Anticancer Agents: From Bench to Bedside

“…Oral resveratrol administration has been found to help prevent colon cancer in people [ 306 ]. In addition, the FDA has approved a clinical trial for gastrointestinal tumors (NCT01476592) [ 371 ]. The effect of resveratrol on notch-1 signaling, the effect on patient therapy, and patient toleration of resveratrol administration were all examined throughout this trial.…”

“…The effect of resveratrol on notch-1 signaling, the effect on patient therapy, and patient toleration of resveratrol administration were all examined throughout this trial. It was discovered that resveratrol injection enhanced cleaved caspase-3 levels in malignant tissue, implying that apoptosis in cancer cells was boosted [ 371 ].…”

Polysaccharide dextran-based conjugate for selective co-delivery of two synergistic drugs docetaxel and docosahexaenoic acid to tumor cells

“…The nanoparticle delivery systems improve the aqueous solubility of DTX and increase its tissues selectivity through passive and active targeting, which subsequently enhances the antitumor effect and alleviates sides effects on normal tissues. Some DTX-based nanoparticles such as albumin-bound DTX (ABI-008), LE-DT, and BIND-014 failed in clinical trials (He et al., 2019 ; Zhang et al., 2019 ; van Eerden et al., 2020 ; Jurczyk et al., 2022 ). The formulation of LE-DT was prepared by electrostatic interaction, of which negatively charged synthetic phospholipids and cholesterol and drugs with opposite charge formed stable liposomes (Zhang et al., 2019 ; Jurczyk et al., 2022 ).…”

“…Some DTX-based nanoparticles such as albumin-bound DTX (ABI-008), LE-DT, and BIND-014 failed in clinical trials (He et al., 2019 ; Zhang et al., 2019 ; van Eerden et al., 2020 ; Jurczyk et al., 2022 ). The formulation of LE-DT was prepared by electrostatic interaction, of which negatively charged synthetic phospholipids and cholesterol and drugs with opposite charge formed stable liposomes (Zhang et al., 2019 ; Jurczyk et al., 2022 ). BIND-014 is composed of DTX encapsulated in a polymer core made of a hydrophobic poly(lactide) surrounded by a hydrophilic poly(ethylene glycol) conjugated with a small molecule of prostate-specific membrane antigen (PSMA)-targeting ligands (Jurczyk et al., 2022 ).…”